Evidence map›Paper›PMID 37059910›Full record

ArticleHandbook of experimental pharmacology2024

Biodegradable Long-Acting Injectables: Platform Technology and Industrial Challenges.

Marieta Duvnjak, Alessia Villois, Farshad Ramazani

Abstract read
PubMed Publisher
In one paragraph

Article in Handbook of experimental pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marieta Duvnjak *Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.
Alessia VilloisTechnical Research and Development, Novartis Pharma AG, Basel, Switzerland.
Farshad Ramazani *Technical Research and Development, Novartis Pharma AG, Basel, Switzerland. farshad.ramazani@novartis.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-acting injectables have been used to benefit patients with chronic diseases. So far, several biodegradable long-acting platform technologies including drug-loaded polymeric microparticles, implants (preformed and in situ forming), oil-based solutions, and aqueous suspension have been established. In this chapter, we summarize all the marketed technology platforms and discuss their challenges regarding development including but not limited to controlling drug release, particle size, stability, sterilization, scale-up manufacturing, etc. Finally, we discuss important criteria to consider for the successful development of long-acting injectables.

Indexed as

Lactic AcidPolyglycolic AcidDelayed-Action PreparationsHumansParticle SizePolylactic Acid-Polyglycolic Acid CopolymerTechnologyDelayed-Action PreparationsLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerControlled releaseExtended releaseLong-acting injectablesMicrocrystal suspensionsMicrospheresOil solutionPLGA microparticlesPreformed and in situ forming implantsSustained release

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.